Ai întrebări despre autism, ADHD, anxietate sau depresie? Găsești ghiduri clare, verificate de specialiști. Acum, acces gratuit.
A study of over 18,500 PD patients identified pathogenic or likely pathogenic GRN variants in 24 patients (0.13%), suggesting that GRN-associated frontotemporal dementia can clinically mimic Parkinson's disease. The findings recommend comprehensive genetic testing including GRN analysis for patients with parkinsonism to improve diagnostic accuracy and inform treatment decisions.
This case report documents an unusual parasomnia where a Parkinson's disease patient ingests levodopa medication while asleep, representing a complex interaction between antiparkinsonian therapy and sleep disorders. The phenomenon illustrates how dopaminergic medications can influence sleep-related behaviors in neurological conditions.
This cross-sectional study of 119 Parkinson's disease patients found yawning-triggered tremor (YRT) significantly more prevalent in PD (18.5%) than controls (2.7%), with notably higher rates in patients with concurrent essential tremor (41.2%) or REM sleep behavior disorder (68.2%). In approximately one-third of cases, YRT preceded motor symptom onset by ~21 months, suggesting it may serve as an early neurodegeneration marker reflecting shared brainstem pathophysiology.
This matched case-control study of 116 Parkinson's disease patients with osteoporotic vertebral fractures and 349 matched controls found that PD is associated with a 2.35-fold higher risk of total fractures and nearly threefold higher upper-thoracic vertebral fractures (T1-T10). Non-vertebral fractures were also significantly more common in PD patients, particularly at the hip, distal radius/ulna, and ribs, suggesting increased fall risk and skeletal fragility beyond bone mineral density reduction.
Drug-induced parkinsonism (DIP) is a common adverse effect of dopamine receptor-blocking agents that mimics idiopathic Parkinson's disease but requires prior exposure to triggering medications for diagnosis. Management involves discontinuing or reducing the offending agent, considering alternative medications with lower DIP risk, and using L-dopa when necessary, with ancillary testing like DaT scans helping distinguish DIP from prodromal Parkinson's disease.